Aligos Therapeutics, Inc. Total Liabilities
Aligos Therapeutics, Inc. (ALGS) had Total Liabilities of $34.44 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Liabilities
us-gaap:Liabilities · last filed 2026-08-06
- 2026-06-30: Liabilities $34.44M.
- 2026-03-31: Liabilities $32.77M.
- 2025-12-31: Liabilities $34.99M.
- 2025-09-30: Liabilities $37.93M.
| Period end | Liabilities |
|---|---|
| 2026-06-30 | $34.44M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $32.77M 10-Q · filed 2026-05-07 |
| 2025-12-31 | $34.99M 10-Q · filed 2026-08-06 |
| 2025-09-30 | $37.93M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $32.84M 10-Q · filed 2025-08-06 |
| 2025-03-31 | $34.25M 10-Q · filed 2025-05-06 |
| 2024-12-31 | $99.07M 10-K · filed 2026-03-05 |
| 2024-09-30 | $38.33M 10-Q · filed 2024-11-06 |
| 2024-06-30 | $41.58M 10-Q · filed 2024-08-06 |
| 2024-03-31 | $68.11M 10-Q · filed 2024-05-07 |
| 2023-12-31 | $59.45M 10-K · filed 2025-03-10 |
| 2023-09-30 | $31.03M 10-Q · filed 2023-11-02 |
| 2023-06-30 | $36.49M 10-Q · filed 2023-08-03 |
| 2023-03-31 | $36.99M 10-Q · filed 2023-05-04 |
| 2022-12-31 | $42.79M 10-K · filed 2024-03-12 |
| 2022-09-30 | $42.06M 10-Q · filed 2022-11-02 |
| 2022-06-30 | $45.54M 10-Q · filed 2022-08-04 |
| 2022-03-31 | $57.58M 10-Q · filed 2022-05-04 |
| 2021-12-31 | $50.64M 10-K · filed 2023-03-09 |
| 2021-09-30 | $46.06M 10-Q · filed 2021-11-04 |
| 2021-06-30 | $42.99M 10-Q · filed 2021-08-05 |
| 2021-03-31 | $39.32M 10-Q · filed 2021-05-10 |
| 2020-12-31 | $45.26M 10-K · filed 2022-03-10 |
| 2020-09-30 | $46.28M 10-Q · filed 2020-11-25 |
| 2019-12-31 | $29.33M 10-K · filed 2021-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| Protara Therapeutics, Inc. (TARA) | United States | $0.198B | -3.22 |